



MICHAEL L. PARSON, GOVERNOR • ROBERT J. KNOELL, DIRECTOR
 TODD RICHARDSON, DIRECTOR
 MO HEALTHNET DIVISION
 P.O. BOX 6500 • JEFFERSON CITY, MO 65102-6500
 WWW.DSS.MO.GOV • 573-751-3425

February 15th, 2024

Dear Pharmaceutical Manufacturer:

The State of Missouri, MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) annual evaluation process. The Division is reviewing specific therapeutic classes and seeking supplemental rebate offers for maximum cost effectiveness for the MO HealthNet pharmacy program. Preferred drugs will be selected in each therapeutic class based on clinical effectiveness and the drugs' relative values within the therapeutic class net of supplemental rebates. These decisions will be made by MHD upon consideration of the recommendations made by the Missouri Drug Prior Authorization Committee (DPAC) and Drug Utilization Review Board (DURB).

Register for Public Comment

Interested parties wishing to provide public comment at an upcoming committee meeting should utilize the below links to register.

[Drug Prior Authorization Committee Meeting Materials](#)
[Drug Utilization Review Board Meeting Materials](#)

At this time, supplemental rebate offers are requested for the following therapeutic categories:

<p>CENTRAL NERVOUS SYSTEM</p> <ul style="list-style-type: none"> Multiple Sclerosis Agents, Injectable Multiple Sclerosis Agents, Oral <p>DERMATOLOGIC AGENTS</p> <ul style="list-style-type: none"> Atopic Dermatitis Agents, Immunomodulators Psoriasis Agents, Oral Psoriasis Agents, Topical <p>ENDOCRINE AND METABOLIC AGENTS</p> <ul style="list-style-type: none"> Alpha Glucosidase Inhibitors Amylin-Analogs Biguanides & Combinations DPP-IV Inhibitors & Combinations GLP-1 Receptor Agonists & Combinations Insulin, Long Acting Insulin, Mixed Insulin, Non-Analogs Insulin, Rapid Acting Growth Hormone Releasing Factors, Select Agents 	<p>ENDOCRINE AND METABOLIC AGENTS (cont.)</p> <ul style="list-style-type: none"> LHRH, GnRH Antagonists, Injectable LHRH, GnRH Antagonists, Oral Meglitinides Oral Sulfonylureas, Second Generation SGLT Inhibitors & Combinations Somatropin Agents TZDs & Combinations <p>HEMATOLOGICAL AGENTS</p> <ul style="list-style-type: none"> Bleeding Disorders Agents Erythropoiesis Stimulating Agents (ESAs) Colony Stimulating Factors Thrombocytopenia Agents <p>IMMUNOLOGIC AGENTS</p> <ul style="list-style-type: none"> Complement Inhibitors, Systemic – **NEW** Neonatal Fc Receptor Antagonists – **NEW** Systemic Immunomodulators, Cryopyrin-Associated Periodic Syndrome (CAPS) Agents Targeted Immune Modulators, IL-6 Receptor Inhibitors[†]
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AUXILIARY AIDS AND SERVICES ARE AVAILABLE UPON REQUEST TO INDIVIDUALS WITH DISABILITIES

TDD / TTY: 800-735-2966

RELAY MISSOURI: 711

IMMUNOLOGIC AGENTS (cont.) <ul style="list-style-type: none"> Targeted Immune Modulators, IL-23 Inhibitors & IL-23/IL-12 Inhibitors[†] Targeted Immune Modulators, JAK Inhibitors[†] Targeted Immune Modulators, Misc. Allergy & Asthma-Related Antibodies Targeted Immune Modulators, Select Agents[†] Targeted Immune Modulators, TNF Inhibitors Targeted Immune Modulators, IL-17A Antibody/IL-17 Receptor Antagonists[†] 	MISCELLANEOUS <ul style="list-style-type: none"> Methotrexate Products MUSCULOSKELETAL <ul style="list-style-type: none"> Exon Skipping Therapies for Muscular Dystrophy – **NEW** Gene Therapies for Muscular Dystrophy – **NEW** Steroids for Muscular Dystrophy – **NEW** RENAL AND GENITOURINARY <ul style="list-style-type: none"> Urinary Tract Antispasmodics
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[†] Preferred agents require an adequate therapeutic six (6) month trial of at least one preferred agent within the Targeted Immune Modulator, Tumor Necrosis Factor (TNF) Inhibitor Class. An adequate six (6) month trial of a preferred Targeted TNF Inhibitors is defined as:

- Combination therapy of 2 TNF inhibitors over six months OR
- Monotherapy of 1 TNF inhibitor over six months

Standard caveats apply if a unique indication exists or if SE/ADR or other precludes the use of TNF Inhibitor or preferred agent within class

Supplemental rebates will begin to accrue on **October 1, 2024** and end **September 30, 2025** for those drugs selected as preferred, unless noted below.

Please note the following deadline:

Final supplemental rebate offers must be submitted to **Gainwell Technologies** to GWTContracting@gainwelltechnologies.com and Sandy.Kapur@gainwelltechnologies.com and Megan.Fast@gainwelltechnologies.com by **5:00 p.m. EST on Monday, March 18th, 2024**

We hope that you will take this opportunity to participate in a program that seeks to retain access to quality pharmaceuticals for Missouri's most vulnerable citizens.

Sincerely,



Josh Moore, PharmD
Director of Pharmacy
MO HealthNet Division